Base de dados : MEDLINE
Pesquisa : E02.183 [Categoria DeCS]
Referências encontradas : 24090 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2409 ir para página                         

  1 / 24090 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29186634
[Au] Autor:Lein DH; Clark D; Graham C; Perez P; Morris D
[Ad] Endereço:Department of Physical Therapy, University of Alabama at Birmingham, SHPB 376, 1720 2nd Avenue South, Birmingham, AL, 35294-1212.
[Ti] Título:A Model to Integrate Health Promotion and Wellness in Physical Therapist Practice: Development and Validation.
[So] Source:Phys Ther;97(12):1169-1181, 2017 Dec 01.
[Is] ISSN:1538-6724
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Background: Globally, physical therapy professional organizations have called for physical therapists to perform lifestyle behavior management during customary care, or health-focused care, due to increasing morbidity and mortality related to noncommunicable diseases. Given the potential for health-focused care to improve health outcomes, physical therapists should integrate health promotion into their daily clinical practice. A clinical model that illustrates necessary steps to deliver health-focused care would be helpful to educate present and future physical therapists. Objective: The purpose of the study was to develop and validate the Health-Focused Physical Therapy Model (HFPTM) for physical inactivity and smoking. Methods: The authors used a mixed method approach. The preliminary model was informed by previous research and the investigators' shared experience in health promotion and physical therapy. An interdisciplinary group of health professionals provided input into the preliminary model by way of a World Café format. Eight physical therapists with health promotion and education expertise then engaged in a Delphi process to establish content validity. Results: World Café participants indicated that: (1) physical therapists are well positioned to engage in health promotion and wellness, and (2) the model facilitates interdisciplinary collaboration and consultation. Delphi process participants reached majority consensus in 1 round. The average model content validity index (CVI) was .915 for physical inactivity and .899 for smoking. Agreement concerning the model schematic was 88% for either behavior. Investigators made few editorial changes after the Delphi process. Limitations: Limitations of this study include using only 2 unhealthy lifestyle behaviors for testing, and performing the testing in a nonclinical setting. Conclusions: An interdisciplinary group of health professionals believes that physical therapists should practice health-focused care and that the HFPTM is a valid model. This model could help physical therapist educators when educating physical therapist students and clinicians to practice health-focused care.
[Mh] Termos MeSH primário: Comportamentos Relacionados com a Saúde
Promoção da Saúde
Modalidades de Fisioterapia
[Mh] Termos MeSH secundário: Protocolos Clínicos
Exercício
Seres Humanos
Estilo de Vida
Educação de Pacientes como Assunto
Reprodutibilidade dos Testes
Fumar
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171130
[St] Status:MEDLINE
[do] DOI:10.1093/ptj/pzx090


  2 / 24090 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29267415
[Au] Autor:Lecomte T; Corbière M
[Ad] Endereço:Département de psychologie, Université de Montréal; Centre de recherche, Institut universitaire en santé mentale de Montréal (CR-IUSMM).
[Ti] Título:[A Group Cognitive-Behavioural Intervention to Prevent Depression Relapse in Individuals Having Recently Returned to Work: Protocol and Feasibility].
[Ti] Título:Une intervention cognitive comportementale de groupe pour prévenir les rechutes chez les employés en processus de retour au travail à la suite d'une dépression : protocole et faisabilité..
[So] Source:Sante Ment Que;42(2):87-103, 2017.
[Is] ISSN:0383-6320
[Cp] País de publicação:Canada
[La] Idioma:fre
[Ab] Resumo:Workplace depression is one of the major causes for sick leave and loss of productivity at work. Many studies have investigated factors predicting return to work for people with depression, including studies evaluating return to work programs and organizational factors. Yet, a paucity of studies have targeted the prevention of depressive relapses at work, even though more than half of those having had a depression will have a depressive relapse in the near future.Objectives This article describes a research protocol involving a novel group intervention based on cognitive behavioural principles with the aim to optimize return to work and diminish risk of depressive relapses.Method This pilot study follows a randomized controlled trial design, with half the participants (N=25) receiving the group intervention and the other half (N=25) receiving usual services. The theoretical and empirical underpinnings of the intervention are described, along with a detailed presentation of the intervention and of the study's objectives. The group intervention consists of 8 sessions whereby Cognitive behavioural therapy (CBT) principles and techniques are applied to the following themes: (1) Coping with stress at work; (2) Recognizing and modifying my dysfunctional beliefs linked to work; (3) Overcoming obstacles linked to work functioning and maintaining work; (4) Negotiating needed work adjustments with the support of the immediate supervisor; (5) Finding my strengths and competencies related to work; (6) Accepting criticism and asserting myself appropriately at work; (7) Uncovering my best coping strategies for work.Results Qualitative information pertaining to the first two cohorts' participants' subjective appreciation of the group experience revealed that the intervention was perceived as very useful by all, with group support, namely harmony and interpersonal support, as well as CBT strategies being mentioned specifically.Conclusion Finally, the potential relevance of the group intervention will be brought forward.
[Mh] Termos MeSH primário: Terapia Cognitiva
Depressão/prevenção & controle
Psicoterapia de Grupo
Retorno ao Trabalho
Prevenção Secundária
[Mh] Termos MeSH secundário: Protocolos Clínicos
Estudos de Viabilidade
Seres Humanos
Projetos Piloto
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE


  3 / 24090 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29378528
[Au] Autor:Elwes F; Borooah S; Aspinall P; Sim PY; Loo CY; Armbrecht AM; Dhillon B; Cackett P
[Ad] Endereço:Royal Infirmary of Edinburgh, Edinburgh, UK.
[Ti] Título:Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab.
[So] Source:BMC Ophthalmol;18(1):20, 2018 Jan 30.
[Is] ISSN:1471-2415
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: To assess the effect of switching patients previously incompletely treated with ranibizumab (RBZ) to aflibercept (AFL) using a pro re nata (PRN) treatment strategy in neovascular age-related macular degeneration (nvAMD). METHODS: A retrospective case series was conducted on patients who had persistent or recurrent intra- and/or sub-retinal fluid treated initially with RBZ and subsequently switched to AFL. The main outcome measures were best corrected visual acuity (BCVA) and central retinal thickness (CRT) measured at different stages of the study. Friedman analysis of variance and Wilcoxon test were used to examine differences in BCVA and CRT. RESULTS: Two hundred and seven eyes from 182 patients were included. BCVA and CRT improved significantly initially following 3 RBZ injections with a mean gain of 3.7 letters (p < 0.001) and a mean loss of 69 µm (p < 0.001) respectively. Following PRN RBZ therapy and immediately prior to switching to AFL (mean 129 weeks), there was a mean loss of 6.7 letters (p < 0.001) BCVA and a mean gain of 24 µm (p < 0.001) CRT. AFL loading resulted in a mean improvement of 0.7 letters (p = 0.28) BCVA and 55 µm (p < 0.001) CRT. At final follow-up following AFL PRN therapy (mean 85 weeks), there was a mean loss of 8.9 letters (p < 0.001) BCVA and a mean gain of 12 µm (p < 0.05) CRT. CONCLUSION: AFL loading resulted in a significant anatomical improvement but no significant change in visual acuity. However, the benefits of switching were gradually lost over time with AFL PRN dosing despite an increased injection rate when compared with RBZ PRN treatment. TRIAL REGISTRATION: Not applicable.
[Mh] Termos MeSH primário: Protocolos Clínicos
Substituição de Medicamentos/métodos
Ranibizumab/administração & dosagem
Receptores de Fatores de Crescimento do Endotélio Vascular/administração & dosagem
Proteínas Recombinantes de Fusão/administração & dosagem
Acuidade Visual
Degeneração Macular Exsudativa/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso de 80 Anos ou mais
Inibidores da Angiogênese/administração & dosagem
Feminino
Seguimentos
Seres Humanos
Injeções Intravítreas
Masculino
Receptores de Fatores de Crescimento do Endotélio Vascular/antagonistas & inibidores
Estudos Retrospectivos
Fatores de Tempo
Tomografia de Coerência Óptica
Resultado do Tratamento
Degeneração Macular Exsudativa/diagnóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Angiogenesis Inhibitors); 0 (Recombinant Fusion Proteins); 15C2VL427D (aflibercept); EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor); ZL1R02VT79 (Ranibizumab)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180131
[St] Status:MEDLINE
[do] DOI:10.1186/s12886-018-0688-3


  4 / 24090 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29465597
[Au] Autor:Yang F; Zou J; Ge L; Tian J; Lee MS; Jun JH; Zhang J
[Ad] Endereço:Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin.
[Ti] Título:Chinese herbal injections for heart failure: A protocol for systematic review and network meta-analyses.
[So] Source:Medicine (Baltimore);97(8):e9973, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Chinese herbal injections (CHIs) are commonly used for the treatment of heart failure in China. Due to the variety of CHIs used in clinic, selecting a suitable CHI for patients with heart failure is vital. This study aims to assess and compare the effect of different CHIs for heart failure using network meta-analysis (NMA). METHODS: Six electronic databases, including PubMed, the Cochrane Central Register of Controlled Trials, Embase, China National Knowledge Infrastructure, Wanfang, and Chinese Biomedical Literature Database will be search from inception to January 2018. Randomized controlled trial (RCT) comparing CHI with another CHI will be included. The primary outcome will be changes in heart function classification and left ventricular ejection fraction. Risk of bias assessment of the included RCTs will be conducted according to the Cochrane Handbook 5.1.0. A Bayesian NMA will be performed using WinBUGS 14 software and the result figures will be generated using Stata 13 software. GRADE will be used to explore the quality of evidence. RESULTS: The results of this NMA will be published in a peer-reviewed journal. CONCLUSION: Our study will generate evidence of CHIs for patients with heart failure and provide suggestions for Chinese medicine clinical practice or guideline. ETHICS AND DISSEMINATION: Ethics approval and patient consent are not required because this study is an NMA based solely on the published literature. The results of this NMA will be submitted to a peer-reviewed journal. PROTOCOL REGISTRATION NUMBER: PROSPERO CRD 42018086740.
[Mh] Termos MeSH primário: Medicamentos de Ervas Chinesas/administração & dosagem
Insuficiência Cardíaca/tratamento farmacológico
Fitoterapia/métodos
[Mh] Termos MeSH secundário: Teorema de Bayes
Protocolos Clínicos
Seres Humanos
Injeções
Metanálise em Rede
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Drugs, Chinese Herbal)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009973


  5 / 24090 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29465596
[Au] Autor:Chen B; Wang Y; He Z; Wang D; Yan X; Xie P
[Ad] Endereço:The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine.
[Ti] Título:Tianma Gouteng decoction for essential hypertension: Protocol for a systematic review and meta-analysis.
[So] Source:Medicine (Baltimore);97(8):e9972, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Essential hypertension is one of the most common chronic diseases, as well as one of the leading risk factors for cardio-cerebrovascular diseases. Tianma Gouteng decoction has been commonly used in clinical practice for patients with essential hypertension. It is important to update the search and evaluation to provide the best available evidence for essential hypertension. Here, we provide a protocol to evaluate the efficacy and safety of Tianma Gouteng decoction (TGD) for essential hypertension. METHODS: Retrieve literature on the TGD treatment for essential hypertension in the databases including PubMed, Cochrane Library, EMBASE, Chinese Biomedical database (CBM), Chinese National Knowledge Infrastructure (CNKI), Wanfang database, and Chinese Science and Technology Periodical database (VIP) on computer. The literature to be collected will be those published from the time when the respective databases were established to January 2018. The therapeutic effects according to the blood pressure (BP) will be accepted as the primary outcomes. We will use RevMan V.5.3 software as well to compute the data synthesis carefully when a meta-analysis is allowed. RESULTS: This study will provide a high-quality synthesis of current evidence of TGD for essential hypertension from several aspects including BP, life quality, heart rate, and adverse events. CONCLUSION: The conclusion of our systematic review will provide evidence to judge whether TGD is an effective intervention for patient with essential hypertension. PROSPERO REGISTRATION NUMBER: PROSPERO CRD 42018082319.
[Mh] Termos MeSH primário: Anti-Hipertensivos/uso terapêutico
Medicamentos de Ervas Chinesas/uso terapêutico
Hipertensão Essencial/tratamento farmacológico
[Mh] Termos MeSH secundário: Pressão Sanguínea/efeitos dos fármacos
Protocolos Clínicos
Frequência Cardíaca/efeitos dos fármacos
Seres Humanos
Qualidade de Vida
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Antihypertensive Agents); 0 (Drugs, Chinese Herbal); 0 (tianma gouteng)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009972


  6 / 24090 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29465598
[Au] Autor:Dong Y; Zhao R; Wang C; Guo T
[Ad] Endereço:First Affiliated Hospital of Unnan University of Traditional Chinese Medicine/Yunnan Province Hospital of Traditional Chinese Medicine.
[Ti] Título:Tuina for osteoporosis: A systematic review protocol.
[So] Source:Medicine (Baltimore);97(8):e9974, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Osteoporosis is one kind of commonly and frequently occurring global disease accompanying with serious complications. As a branch of the subject of Acupuncture-Tuina, tuina is widely applied for osteoporosis alone or combined with other methods in China and other nations while its effective evidence is not clear. Hence, this systematic review protocol purpose is to evaluate the value of its efficacy and safety for osteoporosis. METHODS: This systematic review and meta-analysis will be performed by means of electronic databases including Cochrane Library, Medline, Cochrane Library, Web of Science, EBASE, Springer, WHO International Clinical Trials Registry Platform (ICTRP), China National Knowledge Infrastructure (CNKI), Wanfang database, Chinese Biomedical Literature Database (CBM), Chinese Scientific Journal Database (VIP) and others with valid search strategy probably. The assessment of bias risk, data synthesis, subgroup analysis, and meta-analyses will be conducted using RevMan V.5.3.5 software. RESULTS: This systematic review will present a high-quality evidence for clinicians and might be the first to evaluate the efficacy and safety of tuina for osteoporosis including alleviation of pain, adverse event, spinal motor function improvement as well as improvement of self-care ability and daily living. CONCLUSION: This protocol will determine whether or not tuina is an effective and safety intervention for osteoporosis.
[Mh] Termos MeSH primário: Terapia por Acupuntura/métodos
Medicina Tradicional Chinesa/métodos
Osteoporose/terapia
[Mh] Termos MeSH secundário: Protocolos Clínicos
Seres Humanos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009974


  7 / 24090 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29465586
[Au] Autor:Wang Y; Li X; Li Z; Zhang Y; Wang D
[Ad] Endereço:The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou.
[Ti] Título:YiQiFuMai injection for chronic heart failure: Protocol for a systematic review and meta-analysis.
[So] Source:Medicine (Baltimore);97(8):e9957, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Chronic heart AQ4 failure (CHF) is the final stage of various heart diseases. YiQiFuMai injection (YQFMI) has been widely applied in the treatment of CHF. However, to our knowledge, there has been no systematic review or meta-analysis of randomized controlled trails (RCTs) regarding the effectiveness of this treatment. Here, we provide a protocol to evaluate the efficacy and safety of YQFMI for CHF. METHODS: To evaluate the clinical efficacy of YQFMI in treating CHF, 2 researcher members will independently search the RCTs in the following 8 Chinese and English databases, in which the data collection will be from the time when the respective databases were established to January 2018. The databases will include MEDLINE, EMBASE, Cochrane CENTRAL, CINAHL, the Chinese Biomedical Literature Database, the China National Knowledge Infrastructure, VIP Information and Wanfang Data. The therapeutic effects according to the mortality and the New York Heart Association (NYHA) function classification will be accepted as the primary outcomes. We will use RevMan V.5.3 software as well to compute the data synthesis carefully when a meta-analysis is allowed. RESULTS: This study will provide a high-quality synthesis of current evidence of YQFMI for CHF from several aspects including mortality, NYHA function classification. CONCLUSION: The conclusion of our systematic review will provide evidence to judge whether YQFMI is an effective intervention for CHF.PROSPERO registration number: PROSPERO CRD42017079696.
[Mh] Termos MeSH primário: Cardiotônicos/administração & dosagem
Medicamentos de Ervas Chinesas/administração & dosagem
Insuficiência Cardíaca/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Doença Crônica
Protocolos Clínicos
Feminino
Seres Humanos
Injeções
Masculino
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Cardiotonic Agents); 0 (Drugs, Chinese Herbal); 0 (yi-qi-fu-mai)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009957


  8 / 24090 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:29465549
[Au] Autor:Marques NDSF; Abreu LC; Santos BVD; Neto CFR; Silva JRCD; Braga KKS; Uchôa KDS; Moraes LMS; Ferreira LCP; Ribeiro NG; Santos SLD; Silva TAD; Andrade PE; Raimundo RD
[Ad] Endereço:Laboratory of Study Design and Scientific Writing of the Faculty of Medicine of ABC, Prince of Wales, Santo André/SP-CEP, Brazil.
[Ti] Título:Cardiorespiratory parameters and glycated hemoglobin of patients with type 2 diabetes after a rehabilitation program.
[So] Source:Medicine (Baltimore);97(8):e9321, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Cardiovascular autonomic dysfunction reflex of the pathophysiology of diabetes mellitus (DM) favors an increase in morbidity and mortality related to cardiovascular events, and for this reason has been one of the most studied clinical entities. METHOD: An experimental study of a randomized clinical trial type was therefore proposed to analyze the hemodynamic and glycemic response after the practice of a rehabilitation program in patients with type 2 diabetes mellitus (T2DM). In this clinical trial the patients will initially be submitted to an evaluation protocol that consists of assessing blood pressure, heart rate, Borg scale, respiratory rate, oxygen saturation, distance traveled through the 6-minute walk test, quality of life questionnaire, Pittsburgh sleep quality questionnaire, and still glycated hemoglobin and heart rate variability through the cardiofrequency meter. After careful evaluation of the patients, they will be submitted to a metabolic rehabilitation program composed of aerobic and resisted exercises, performed for 12 weeks, in 3 weekly meetings of 60 minutes each. With such evaluations, it will be possible to construct with evidence that it is possible to work safer metabolic rehabilitation programs in patients with T2DM or other diseases that generate cardiovascular risks, guaranteeing them an improvement in cardiorespiratory fitness, hemodynamic and glycemic variables, allowing improvement of the quality of life. ETHICS AND DISSEMINATION: The protocol is approved by the host institution's ethics committee under the number 1.616.721. Results will be disseminated via peer-reviewed journal articles and conferences. This clinical trial is registered at ClinicalTrials.gov identifier: NCT3094767.
[Mh] Termos MeSH primário: Diabetes Mellitus Tipo 2
Exercício/fisiologia
Hemoglobina A Glicada/análise
Treinamento de Resistência/métodos
[Mh] Termos MeSH secundário: Adulto
Glicemia/análise
Pressão Sanguínea
Protocolos Clínicos
Diabetes Mellitus Tipo 2/sangue
Diabetes Mellitus Tipo 2/fisiopatologia
Diabetes Mellitus Tipo 2/reabilitação
Feminino
Frequência Cardíaca
Seres Humanos
Masculino
Consumo de Oxigênio
Qualidade de Vida
Sono
Inquéritos e Questionários
Resultado do Tratamento
Teste de Caminhada
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Blood Glucose); 0 (Glycated Hemoglobin A); 0 (hemoglobin A1c protein, human)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009321


  9 / 24090 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29465538
[Au] Autor:Liu F; Wang W; Wang C; Peng X
[Ad] Endereço:Department of Pharmacy.
[Ti] Título:Enhanced recovery after surgery (ERAS) programs for esophagectomy protocol for a systematic review and meta-analysis.
[So] Source:Medicine (Baltimore);97(8):e0016, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Esophageal cancer is one of the worst malignant digestive neoplasms with poor treatment outcomes. Esophagectomy plays an important role and offers a potential curable chance to these patients. However, esophagectomy with radical lymphadenectomy is known as one of the most invasive digestive surgeries which are associated with high morbidity and mortality. The enhanced recovery after surgery (ERAS) protocol is a patient-centered, surgeon-led system combining anesthesia, nursing, nutrition, and psychology, which is designed for reducing complications, promoting recovery, and improving treatment outcomes. This systematic review and meta-analysis is aiming at how beneficial, and to what extent ERAS really will be. METHODS: A systematic literature search will be performed through January 2018 using MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and Google Scholar for relevant articles published in any language. Randomized controlled trials, prospective cohort studies, and propensity-matched comparative studies will be included. All meta-analyses will be performed using Review Manager software. The quality of the studies will be evaluated using the guidelines listed in the Cochrane Handbook. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statements will be followed until the findings of the systematic review and meta-analysis are reported. RESULTS: The results of this systematic review and meta-analysis will be published in a peer-reviewed journal. CONCLUSION: Our study will draw an objective conclusion of the comparisons between ERAS and conventional care in aspects of perioperative outcomes and provide level I evidences for clinical decision makings.
[Mh] Termos MeSH primário: Neoplasias Esofágicas/cirurgia
Esofagectomia/reabilitação
Cuidados Pós-Operatórios/métodos
Complicações Pós-Operatórias/reabilitação
[Mh] Termos MeSH secundário: Protocolos Clínicos
Esofagectomia/efeitos adversos
Feminino
Seres Humanos
Masculino
Complicações Pós-Operatórias/etiologia
Recuperação de Função Fisiológica
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000010016


  10 / 24090 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28449699
[Au] Autor:Munteanu SE; Landorf KB; McClelland JA; Roddy E; Cicuttini FM; Shiell A; Auhl M; Allan JJ; Buldt AK; Menz HB
[Ad] Endereço:Discipline of Podiatry, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Melbourne, VIC, 3086, Australia. s.munteanu@latrobe.edu.au.
[Ti] Título:Shoe-stiffening inserts for first metatarsophalangeal joint osteoarthritis (the SIMPLE trial): study protocol for a randomised controlled trial.
[So] Source:Trials;18(1):198, 2017 Apr 27.
[Is] ISSN:1745-6215
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: This article describes the design of a parallel-group, participant- and assessor-blinded randomised controlled trial comparing the effectiveness of shoe-stiffening inserts versus sham shoe insert(s) for reducing pain associated with first metatarsophalangeal joint (MTPJ) osteoarthritis (OA). METHODS: Ninety participants with first MTPJ OA will be randomised to receive full-length shoe-stiffening insert(s) (Carbon Fibre Spring Plate, Paris Orthotics, Vancouver, BC, Canada) plus rehabilitation therapy or sham shoe insert(s) plus rehabilitation therapy. Outcome measures will be obtained at baseline, 4, 12, 24 and 52 weeks; the primary endpoint for assessing effectiveness being 12 weeks. The primary outcome measure will be the foot pain domain of the Foot Health Status Questionnaire (FHSQ). Secondary outcome measures will include the function domain of the FHSQ, severity of first MTPJ pain (using a 100-mm Visual Analogue Scale), global change in symptoms (using a 15-point Likert scale), health status (using the Short-Form-12® Version 2.0 and EuroQol (EQ-5D-5L™) questionnaires), use of rescue medication and co-interventions, self-reported adverse events and physical activity levels (using the Incidental and Planned Activity Questionnaire). Data will be analysed using the intention-to-treat principle. Economic analysis (cost-effectiveness and cost-utility) will also be performed. In addition, the kinematic effects of the interventions will be examined at 1 week using a three-dimensional motion analysis system and multisegment foot model. DISCUSSION: This study will determine whether shoe-stiffening inserts are a cost-effective intervention for relieving pain associated with first MTPJ OA. The biomechanical analysis will provide useful insights into the mechanism of action of the shoe-stiffening inserts. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry, identifier: ACTRN12616000552482 . Registered on 28 April 2016.
[Mh] Termos MeSH primário: Protocolos Clínicos
Órtoses do Pé
Articulação Metatarsofalângica/fisiopatologia
Osteoartrite/terapia
[Mh] Termos MeSH secundário: Fenômenos Biomecânicos
Análise Custo-Benefício
Seres Humanos
Osteoartrite/reabilitação
Avaliação de Resultados (Cuidados de Saúde)
Cooperação do Paciente
Sapatos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1186/s13063-017-1936-1



página 1 de 2409 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde